Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Repligen Corp (RGEN)
NASDAQ:RGEN
Repligen (RGEN) Stock Price & Analysis
907 Followers
RGEN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$110.45 - $211.13
Previous Close$123.81
Volume847.03K
Average Volume (3M)695.69K
Market Cap
$6.92B
Enterprise Value$6.88B
Total Cash (Recent Filing)$751.32M
Total Debt (Recent Filing)$711.80M
Price to Earnings (P/E)490.5
Beta2.01
Next Earnings
Jul 30, 2024EPS Estimate
$0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.25
Shares Outstanding55,875,894
10 Day Avg. Volume1,168,081
30 Day Avg. Volume695,686
Standard Deviation0.12
R-Squared0.21
Alpha0.00698
Financial Highlights & Ratios
Price to Book (P/B)12.00
Price to Sales (P/S)10.96
Price to Cash Flow (P/CF)60.20
P/FCF Ratio82.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue15.08
Enterprise Value/Gross Profit24.15
Enterprise Value/Ebitda77.12
Forecast
1Y Price Target
$183.40Price Target Upside48.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
Repligen News
PremiumCompany Announcements
Repligen Announces Executive Leadership Transition and Compensation Plans
Bulls Say, Bears Say
Bulls Say
Company PerformanceTony Hunt has been one of the most highly respected and trusted CEOs over the past decade as he grew the company's revenues from ~$63M in 2014 to $639M in 2023, representing a CAGR of over 30%.
LeadershipCEO-elect Loeillot confirmed that he expects double digit growth for Repligen over the next decade and outlined his top 3 priorities.
Market PositionRepligen still holds the #5 market position and ~5% market share in the bioprocessing market, delivering 20%+ growth longer term.
Bears Say
Financial PerformanceTotal company orders were down approximately 7% both sequentially and year-over-year this quarter.
ManagementThe announcement of the succession plan for CEO Tony Hunt, without reiterating 2024 guidance, has driven investor fears regarding the bioprocessing recovery.
Market SentimentConcerns about bioprocessing recovery have intensified, especially after participants at a recent BIO conference signaled a slower-than-expected recovery.
---
Ownership Overview
30.17% Insiders
44.01% Mutual Funds
24.39% Other Institutional Investors
1.44% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RGEN FAQ
What was Repligen Corp’s price range in the past 12 months?
Repligen Corp lowest stock price was $110.45 and its highest was $211.13 in the past 12 months.
What is Repligen Corp’s market cap?
Currently, no data Available
When is Repligen Corp’s upcoming earnings report date?
Repligen Corp’s upcoming earnings report date is Jul 30, 2024 which is in 8 days.
How were Repligen Corp’s earnings last quarter?
Repligen Corp released its earnings results on May 01, 2024. The company reported $0.28 earnings per share for the quarter, missing the consensus estimate of $0.301 by -$0.021.
Is Repligen Corp overvalued?
According to Wall Street analysts Repligen Corp’s price is currently Undervalued.
Does Repligen Corp pay dividends?
Repligen Corp does not currently pay dividends.
What is Repligen Corp’s EPS estimate?
Repligen Corp’s EPS estimate is $0.33.
How many shares outstanding does Repligen Corp have?
Repligen Corp has 55,875,893 shares outstanding.
What happened to Repligen Corp’s price movement after its last earnings report?
Repligen Corp reported an EPS of $0.28 in its last earnings report, missing expectations of $0.301. Following the earnings report the stock price went down -3.557%.
Which hedge fund is a major shareholder of Repligen Corp?
Among the largest hedge funds holding Repligen Corp’s share is Sands Capital Management LLC. It holds Repligen Corp’s shares valued at 264M.
---
Repligen Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$183.40 (48.13% Upside)
$183.40 (48.13% Upside)
Blogger Sentiment
Neutral
RGEN Sentiment 50%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 31.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $600.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.8%
Last 30 Days ▲ 11.3%
Last 30 Days ▲ 11.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.93%
12-Months-Change
Fundamentals
Return on Equity
0.76%
Trailing 12-Months
Asset Growth
12.25%
Trailing 12-Months
Company Description
Repligen Corp
Repligen Corp. provides advanced bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. The firm serves through the following product lines: Chromatography; Filtration; and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The OEM products are represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification, and cell culture growth factor products. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.
---
RGEN Earnings Call
Q1 2024
0:00 / 0:00
---
RGEN Revenue Breakdown
99.94% Product revenue
0.06% Royalty and other income
---
RGEN Stock 12 Month Forecast
Average Price Target
$183.40
▲(48.13% Upside)
Technical Analysis
Atara Biotherapeutics
―
Alnylam Pharma
―
Arrowhead Pharmaceuticals
―
Fate Therapeutics
―
Best Analysts Covering RGEN
1 Year
1 Year Success Rate
9/17 ratings generated profit
1 Year Average Return
+24.46%
reiterated a buy rating last month
Copying Daniel Arias's trades and holding each position for 1 Year would result in 52.94% of your transactions generating a profit, with an average return of +24.46% per trade.
---